Current News

Contact | Print version | PDF version | Send article | RSS feed

Silence Therapeutics announces that the entire shareholding held by Introgen has been placed with existing and new shareholder

21 Jan 2008 - Silence Therapeutics plc announced that a number of existing institutional shareholders have increased their shareholdings in the Company, while several additional investors have become new shareholders. These shareholders have purchased their shares from Introgen Inc., which has disposed of its entire holding of 7,478,261 ordinary shares in Silence Therapeutics, representing approximately 6.2% of the issued share capital of the Company.
 
The shares were purchased at the prevailing market price of 56.75p per share and as necessary further regulatory announcements concerning this transaction will follow in due course.